# Scott M. Wasserman

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/scott-m-wasserman/

## Facts

| Field | Value |
| --- | --- |
| Citations | 26,136 |
| Field | Lipoproteins and Cardiovascular Health |
| h-index | 62 |
| i10-index | 99 |
| Last Known Institution | Amgen (United States) |
| OpenAlex ID | https://openalex.org/A5086317157 |
| ORCID iD | https://orcid.org/0000-0003-0634-6021 |
| Works | 180 |

## Researcher papers

- [Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease](https://scholariq.org/papers/evolocumab-and-clinical-outcomes-in-patients-with-cardiovascular-disease/)
- [Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia](https://scholariq.org/papers/effect-of-evolocumab-or-ezetimibe-added-to-moderate-or-high-intensity-statin/)
- [Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study](https://scholariq.org/papers/efficacy-safety-and-tolerability-of-a-monoclonal-antibody-to-proprotein-2/)
- [Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study](https://scholariq.org/papers/efficacy-safety-and-tolerability-of-a-monoclonal-antibody-to-proprotein/)
- [The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial](https://scholariq.org/papers/the-effects-of-the-cardiac-myosin-activator-omecamtiv-mecarbil-on-cardiac/)

## Researcher topics

- [Lipoproteins and Cardiovascular Health](https://scholariq.org/topics/lipoproteins-and-cardiovascular-health/)
- [Atherosclerosis and Cardiovascular Diseases](https://scholariq.org/topics/atherosclerosis-and-cardiovascular-diseases/)
- [Pharmaceutical Economics and Policy](https://scholariq.org/topics/pharmaceutical-economics-and-policy/)
- [Diabetes, Cardiovascular Risks, and Lipoproteins](https://scholariq.org/topics/diabetes-cardiovascular-risks-and-lipoproteins/)
- [Biosimilars and Bioanalytical Methods](https://scholariq.org/topics/biosimilars-and-bioanalytical-methods/)

## Researcher university

- [Amgen (United States)](https://scholariq.org/institutions/amgen-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.